Literature DB >> 33295879

Graves' disease: introducing new genetic and epigenetic contributors.

Ehsan Razmara1,2, Mehrnaz Salehi3, Saeed Aslani1, Amirreza Bitaraf1,4, Hassan Yousefi5, Jonathan Rosario Colón5, Mahdi Mahmoudi1,6.   

Abstract

Autoimmune thyroid disease (AITD) accounts for 90% of all thyroid diseases and affects 2-5% of the population with remarkable familial clustering. Among AITDs, Graves' disease (GD) is a complex disease affecting thyroid function. Over the last two decades, case-control studies using cutting-edge gene sequencing techniques have detected various susceptible loci that may predispose individuals to GD. It has been presumed that all likely associated genes, variants, and polymorphisms might be responsible for 75-80% of the heritability of GD. As a result, there are implications concerning the potential contribution of environmental and epigenetic factors in the pathogenesis of GD, including its initiation, progression, and development. Numerous review studies have summarized the contribution of genetic factors in GD until now, but there are still some key questions and notions that have not been discussed concerning the interplay of genetic, epigenetic, and immunological factors. With this in mind, this review discusses some newly-identified loci and their potential roles in the pathogenicity of GD. This may lead to the identification of new, promising therapeutic targets. Here, we emphasized principles, listed all the reported disease-associated genes and polymorphisms, and also summarized the current understanding of the epigenetic basis of GD.

Entities:  

Keywords:  Graves’ disease; autoimmune hyperthyroidism; autoimmune thyroid disease; genetic and epigenetic factors

Mesh:

Substances:

Year:  2021        PMID: 33295879     DOI: 10.1530/JME-20-0078

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  6 in total

1.  miR-199a Downregulation as a Driver of the NOX4/HIF-1α/VEGF-A Pathway in Thyroid and Orbital Adipose Tissues from Graves' Patients.

Authors:  Julie Craps; Virginie Joris; Lelio Baldeschi; Chantal Daumerie; Alessandra Camboni; Antoine Buemi; Benoit Lengelé; Catherine Behets; Antonella Boschi; Michel Mourad; Marie-Christine Many; Chantal Dessy
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

Review 2.  SMAD4 contributes to chondrocyte and osteocyte development.

Authors:  Katayoon Pakravan; Ehsan Razmara; Bashdar Mahmud Hussen; Fatemeh Sattarikia; Majid Sadeghizadeh; Sadegh Babashah
Journal:  J Cell Mol Med       Date:  2021-11-28       Impact factor: 5.310

3.  Graves' Disease and Rheumatoid Arthritis: A Bidirectional Mendelian Randomization Study.

Authors:  Dide Wu; Wei Xian; Shubin Hong; Boyuan Liu; Haipeng Xiao; Yanbing Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-17       Impact factor: 5.555

4.  Comprehensive Analysis of lncRNA Expression Profile and the Potential Role of ENST00000604491 in Graves' Disease.

Authors:  Yingzhao Liu; Junli Zou; Juan Xu; Xuehua Wang; Jie Xing; Li Wang; Huiyong Peng
Journal:  J Immunol Res       Date:  2022-04-25       Impact factor: 4.493

5.  A Signature of Three microRNAs Is a Potential Diagnostic Biomarker for Glioblastoma

Authors:  Ali Hosein Yazdi; Vajiheh Zarrinpour; Elham Moslemi; Mohammad Mahdi Forghanifard
Journal:  Iran Biomed J       Date:  2022-07-01

6.  Identification of a six-microRNA signature as a potential diagnostic biomarker in breast cancer tissues.

Authors:  Mojdeh Mahmoudian; Ehsan Razmara; Bashdar Mahmud Hussen; Mandana Simiyari; Nazanin Lotfizadeh; Hoda Motaghed; Arefeh Khazraei Monfared; Maryam Montazeri; Sadegh Babashah
Journal:  J Clin Lab Anal       Date:  2021-09-15       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.